We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
News & Views

Company Profile: Biocompatibles International plc: local drug delivery for targeted therapies

    Donald Coppen

    Director of Partnering & Licensing, Biocompatible International plc, Chapman House, Weydon Lane, Farnham, Surrey, GU9 8QL, UK.

    Search for more papers by this author

    Email the corresponding author at donald.coppen@biocompatibles.com

    Published Online:8 Mar 2010https://doi.org/10.2217/rme.10.5

    Abstract

    Biocompatibles International plc is focused on the development of targeted therapies for a range of indications, including oncology, neurology and cardiology. By delivering the therapy directly to the site of a localized disease numerous benefits can be achieved, including the targeting of a very high therapeutic dose to the required location and reduced systemic toxicity. As part of this strategy the company is now a leader in the field of using locally placed stem cells to make and deliver therapeutically active peptide drugs. The encapsulated cells (CellBeads®), modified to produce a potent anti-apoptotic peptide, CM1, are currently being evaluated in a Phase I/IIa study for the treatment of stroke and in preclinical models of acute myocardial infarction.

    Bibliography

    • 1  Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project – 1981–86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J. Neurol. Neurosurg. Psychiatry53(1),16–22 (1990).
      Medline CASGoogle Scholar
    • 2  Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF: Spontaneous intracerebral hemorrhage. N. Engl. J. Med.344(19),1450–1460 (2001).
      Medline CASGoogle Scholar
    • 3  Sacco S, Marini C, Toni D, Olivieri L, Carolei A: Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke40(2),394–399 (2009).
      MedlineGoogle Scholar
    • 4  Yang BY, Betz AL, Chenevert TL, Brunberg JA, Hoff JT: Experimental intracerebral hemorrhage: relationship between brain edema, blood flow, and blood–brain barrier permeability in rats. J. Neurosurg.81,93–102 (1994).
      Medline CASGoogle Scholar
    • 5  Fewel ME, Thompson BG, Hoff JT: Spontaneous intracerebral hemorrhage: a review. Neurosurg. Focus15(4),1–16 (2003).
      MedlineGoogle Scholar
    • 6  Hankey GJ: Evacuation of intracerebral hematoma is likely to be beneficial–against. Stroke34,1568 (2003).
      MedlineGoogle Scholar
    • 7  Broderick JP, Brott T, Tomsick T, Miller R, Huster G: Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J. Neurosurg.78(2),188–191 (1993).
      Medline CASGoogle Scholar
    • 8  Yoo SW, Kim SS, Lee SY et al.: Mesenchymal stem cells promote proliferation of endogenous neural stem cells and survival of newborn cells in a rat stroke model. Exp. Mol. Med.40(4),387–397 (2008).
      Medline CASGoogle Scholar
    • 9  Deng YB, Ye WB, Hu ZZ et al.: Intravenously administered BMSCs reduce neuronal apoptosis and promote neuronal proliferation through the release of VEGF after stroke in rats. Neurol. Res. (2009) (Epub ahead of print).
      MedlineGoogle Scholar
    • 10  Li Y, Perry T, Kindy MS et al.: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl Acad. Sci. USA106(4),1285–1290 (2009).
      Medline CASGoogle Scholar
    • 11  Meir JJ, Nauck MA: Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab. Res. Rev.21(2),91–117 (2005).
      MedlineGoogle Scholar
    • 12  Heile AMB, Wallrapp C, Klinge PM et al.: Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci. Lett.463(3),176–181 (2009).
      Medline CASGoogle Scholar
    • 13  Taylor DA, Zenovich AG: Cardiovascular cell therapy and endogenous repair. Diabetes Obes. Metab.10(Suppl. 4),5–15 (2008).
      MedlineGoogle Scholar
    • 14  Krijnen PA, Nijmeijer R, Meijer CJ, Visser CA, Hack CE, Niessen HW: Apoptosis in myocardial ischaemia and infarction. J. Clin. Pathol.55(11),801–811 (2002).
      Medline CASGoogle Scholar
    • 15  Duffy GP, Ahsan T, O’Brien T, Barry F, Nerem RM: Bone marrow-derived mesenchymal stem cells promote angiogenic processes in a time- and dose-dependent manner in vitro.Tissue Eng. Part A15(9),2459–2470 (2009).
      Medline CASGoogle Scholar
    • 16  Nikolaidis LA, Mankad S, Sokos GG et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation109(8),962–965 (2004).
      Medline CASGoogle Scholar
    • 17  Bose AK, Mocanu MM, Carr RD, Yellon DM: Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc. Drugs Ther.21(4),253–256 (2007).
      Medline CASGoogle Scholar
    • 18  Geigle P, Wallrapp C, Lewis A et al.: Encapsulated mesenchymal stem cells for the local, long-term delivery of GLP-1 for use in the treatment of acute myocardial infarction. Presented at: World Stem Cell Summit 2009. Baltimore, MA, USA, 21–23 September 2009.
      Google Scholar
    • 19  Farrell K, Hawthorne M, Wallrapp C et al.: GLP-1 CellBeads enhance myocardial angiogenesis and improve LV function. Eur Heart J.30(Abstract Suppl.),495 (2009).
      Google Scholar